

University of Groningen

Serotonin, cortisol, and stress-related psychopathology

Tanke, Marit Aline Christine

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2009

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Tanke, M. A. C. (2009). *Serotonin, cortisol, and stress-related psychopathology: from bench to bed*. s.n.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

References

- (1) Selye H. *The Stress of Life*. 1956. New York, McGraw-Hill.
- (2) Leonard BE. The HPA and immune axes in stress: the involvement of the serotonergic system. *Eur Psychiatry* 2005 Oct;20 Suppl 3:S302-S306.
- (3) Sapolsky R. Taming stress. *Sci Am* 2003 Sep;289(3):86-95.
- (4) Sapolsky RM. Stress and plasticity in the limbic system. *Neurochem Res* 2003 Nov;28(11):1735-42.
- (5) Kendler KS, Karkowski LM, Prescott CA. Causal relationship between stressful life events and the onset of major depression. *Am J Psychiatry* 1999 Jun;156(6):837-41.
- (6) Kendler KS, Thornton LM, Gardner CO. Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the "kindling" hypothesis. *Am J Psychiatry* 2000 Aug;157(8):1243-51.
- (7) Tennant C. Work-related stress and depressive disorders. *J Psychosom Res* 2001 Nov;51(5):697-704.
- (8) Paykel ES. Life events and affective disorders. *Acta Psychiatr Scand Suppl* 2003;(418):61-6.
- (9) Schindler BA. Stress, affective disorders, and immune function. *Med Clin North Am* 1985 May;69(3):585-97.
- (10) Ormel J, Oldehinkel AJ, Brilman EI. The interplay and etiological continuity of neuroticism, difficulties, and life events in the etiology of major and subsyndromal, first and recurrent depressive episodes in later life. *Am J Psychiatry* 2001 Jun;158(6):885-91.
- (11) Kendler KS, Kuhn JW, Vittum J, Prescott CA, Riley B. The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. *Arch Gen Psychiatry* 2005 May;62(5):529-35.
- (12) Belmaker RH, Agam G. Major depressive disorder. *N Engl J Med* 2008 Jan 3;358(1):55-68.
- (13) Caspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. *Nat Rev Neurosci* 2006 Jul;7(7):583-90.
- (14) Cannon WB. *The Wisdom of the Body*. New York: W. W. Norton & Co., Inc., 1932.
- (15) Stamp JA, Herbert J. Multiple immediate-early gene expression during physiological and endocrine adaptation to repeated stress. *Neuroscience* 1999;94(4):1313-22.
- (16) Chen X, Herbert J. Regional changes in c-fos expression in the basal forebrain and brainstem during adaptation to repeated stress: correlations with cardiovascular, hypothermic and endocrine responses. *Neuroscience* 1995 Feb;64(3):675-85.
- (17) Umemoto S, Kawai Y, Ueyama T, Senba E. Chronic glucocorticoid administration as well as repeated stress affects the subsequent acute immobilization stress-induced expression of immediate early genes but not that of NGFI-A. *Neuroscience* 1997 Oct;80(3):763-73.

References

- (18) Melia KR, Ryabinin AE, Schroeder R, Bloom FE, Wilson MC. Induction and habituation of immediate early gene expression in rat brain by acute and repeated restraint stress. *J Neurosci* 1994 Oct;14(10):5929-38.
- (19) Selye H. Forty years of stress research: principal remaining problems and misconceptions. *Can Med Assoc J* 1976 Jul 3;115(1):53-6.
- (20) Paris JM, Lorens SA, Van de Kar LD, Urban JH, Richardson-Morton KD, Bethea CL. A comparison of acute stress paradigms: hormonal responses and hypothalamic serotonin. *Physiol Behav* 1987;39(1):33-43.
- (21) Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. *Eur J Pharmacol* 2003 Feb 28;463(1-3):235-72.
- (22) Reul JM, de Kloet ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. *Endocrinology* 1985 Dec;117(6):2505-11.
- (23) Meijer OC, de Kloet ER. Corticosterone and serotonergic neurotransmission in the hippocampus: functional implications of central corticosteroid receptor diversity. *Crit Rev Neurobiol* 1998;12(1-2):1-20.
- (24) Reul JM, van den Bosch FR, de Kloet ER. Relative occupation of type-I and type-II corticosteroid receptors in rat brain following stress and dexamethasone treatment: functional implications. *J Endocrinol* 1987 Dec;115(3):459-67.
- (25) de Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and disease. *Endocr Rev* 1998 Jun;19(3):269-301.
- (26) Kunugi H, Ida I, Owashii T, Kimura M, Inoue Y, Nakagawa S, et al. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a Multicenter Study. *Neuropsychopharmacology* 2006 Jan;31(1):212-20.
- (27) Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. *Mol Psychiatry* 2002;7(3):254-75.
- (28) Holsboer F. The corticosteroid receptor hypothesis of depression. *Neuropsychopharmacology* 2000 Nov;23(5):477-501.
- (29) Burke HM, Davis MC, Otte C, Mohr DC. Depression and cortisol responses to psychological stress: a meta-analysis. *Psychoneuroendocrinology* 2005 Oct;30(9):846-56.
- (30) Owens MJ, Nemeroff CB. The role of CRF in the pathophysiology of affective and anxiety disorders. In: Vale W. Chichester, editor. *Corticotropin Releasing Factor CIBA Symposium*. Wiley: 1993. p. 296-319.
- (31) Sachar EJ, Hellman L, Roffwarg HP, Halpern FS, Fukushima DK, Gallagher TF. Disrupted 24-hour patterns of cortisol secretion in psychotic depression. *Arch Gen Psychiatry* 1973 Jan;28(1):19-24.
- (32) Matza LS, Revicki DA, Davidson JR, Stewart JW. Depression with atypical features in the National Comorbidity Survey: classification, description, and consequences. *Arch Gen Psychiatry* 2003 Aug;60(8):817-26.
- (33) Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. *J Psychosom Res* 2002 Oct;53(4):865-71.
- (34) Posener JA, DeBattista C, Williams GH, Chmura KH, Kalehzan BM, Schatzberg AF. 24-

References

- Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. *Arch Gen Psychiatry* 2000 Aug;57(8):755-60.
- (35) Yehuda R, Teicher MH, Trestman RL, Levengood RA, Siever LJ. Cortisol regulation in posttraumatic stress disorder and major depression: a chronobiological analysis. *Biol Psychiatry* 1996 Jul 15;40(2):79-88.
- (36) Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. *Am J Psychiatry* 2003 Sep;160(9):1554-65.
- (37) Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. *Biological Psychiatry* 2001 Mar 1;49(5):391-404.
- (38) Reul JM, Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. *Curr Opin Pharmacol* 2002 Feb;2(1):23-33.
- (39) Zobel AW, Yassouridis A, Frieboes RM, Holsboer F. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. *Am J Psychiatry* 1999 Jun;156(6):949-51.
- (40) Appelhof BC, Huyser J, Verweij M, Brouwer JP, van Dyck R, Fliers E, et al. Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression). *Biol Psychiatry* 2006 Apr 15;59(8):696-701.
- (41) Gerken A, Maier W, Holsboer F. Weekly monitoring of dexamethasone suppression response in depression: its relationship to change of body weight and psychopathology. *Psychoneuroendocrinology* 1985;10(3):261-71.
- (42) Ribeiro SC, Tandon R, Grunhaus L, Greden JF. The DST as a predictor of outcome in depression: a meta-analysis. *Am J Psychiatry* 1993 Nov;150(11):1618-29.
- (43) Stevens KE, Bullock AE, Collins AC. Chronic corticosterone treatment alters sensory gating in C3H mice. *Pharmacol Biochem Behav* 2001 Jul;69(3-4):359-66.
- (44) van den Buuse BM, van Acker SA, Fluttert MF, de Kloet ER. Involvement of corticosterone in cardiovascular responses to an open-field novelty stressor in freely moving rats. *Physiol Behav* 2002 Feb 1;75(1-2):207-15.
- (45) Stamp J, Herbert J. Corticosterone modulates autonomic responses and adaptation of central immediate-early gene expression to repeated restraint stress. *Neuroscience* 2001;107(3):465-79.
- (46) de Kloet ER, Grootendorst J, Karssen AM, Oitzl MS. Gene x environment interaction and cognitive performance: animal studies on the role of corticosterone. *Neurobiol Learn Mem* 2002 Nov;78(3):570-7.
- (47) Fadda F, Cocco S, Stancampiano R. A physiological method to selectively decrease brain serotonin release. *Brain Res Brain Res Protoc* 2000 Jul;5(3):219-22.
- (48) Moja EA, Cipolla P, Castoldi D, Tofanetti O. Dose-Response Decrease in Plasma Tryptophan and in Brain Tryptophan and Serotonin After Tryptophan-Free Amino-Acid Mixtures in Rats. *Life Sciences* 1989;44(14):971-6.
- (49) Biggio G, Fadda F, Fanni P, Tagliamonte A, Gessa GL. Rapid depletion of serum tryptophan, brain tryptophan, serotonin and 5-hydroxyindoleacetic acid by a tryptophan-free diet. *Life Sci* 1974 Apr 1;14(7):1321-9.

References

- (50) Lieben CK, Blokland A, Westerink B, Deutz NE. Acute tryptophan and serotonin depletion using an optimized tryptophan-free protein-carbohydrate mixture in the adult rat. *Neurochem Int* 2004 Jan;44(1):9-16.
- (51) Barnes NM, Sharp T. A review of central 5-HT receptors and their function. *Neuropharmacology* 1999 Aug;38(8):1083-152.
- (52) Bosker FJ, Klompmakers A, Westenberg HG. Postsynaptic 5-HT1A receptors mediate 5-hydroxytryptamine release in the amygdala through a feedback to the caudal linear raphe. *Eur J Pharmacol* 1997 Aug 27;333(2-3):147-57.
- (53) Blier P, Pineyro G, el MM, Bergeron R, de MC. Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. *Ann N Y Acad Sci* 1998 Dec 15;861:204-16.
- (54) Ansoorge MS, Zhou M, Lira A, Hen R, Gingrich JA. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. *Science* 2004 Oct 29;306(5697):879-81.
- (55) Lucki I. The spectrum of behaviors influenced by serotonin. *Biol Psychiatry* 1998 Aug 1;44(3):151-62.
- (56) Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. *Lancet* 2000 Mar 11;355(9207):911-8.
- (57) Schildkraut JJ. The Catecholamine Hypothesis of Affective Disorders - A Review of Supporting Evidence. *Am J Psychiatry* 1965;122:509-22.
- (58) Cowen PJ, Parry-Billings M, Newsholme EA. Decreased plasma tryptophan levels in major depression. *J Affect Disord* 1989 Jan;16(1):27-31.
- (59) Brown GL, Linnoila MI. CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. *J Clin Psychiatry* 1990 Apr;51 Suppl:31-41.
- (60) van Praag HM, Korf J, Puite J. 5-Hydroxyindoleacetic acid levels in the cerebrospinal fluid of depressive patients treated with probenecid. *Nature* 1970 Mar 28;225(5239):1259-60.
- (61) Sandyk R. L-tryptophan in neuropsychiatric disorders: a review. *Int J Neurosci* 1992 Nov;67(1-4):127-44.
- (62) Neumeister A, Hu XZ, Luckenbaugh DA, Schwarz M, Nugent AC, Bonne O, et al. Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. *Arch Gen Psychiatry* 2006 Sep;63(9):978-86.
- (63) Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. *Mol Psychiatry* 2007 Apr;12(4):331-59.
- (64) Jans LA, Riedel WJ, Markus CR, Blokland A. Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. *Mol Psychiatry* 2006 Dec 12.
- (65) Van der Does AJ. The effects of tryptophan depletion on mood and psychiatric symptoms. *J Affect Disord* 2001 May;64(2-3):107-19.
- (66) Walderhaug E, Magnusson A, Neumeister A, Lappalainen J, Lunde H, Refsum H, et al. Interactive effects of sex and 5-HTTLPR on mood and impulsivity during tryptophan depletion in healthy people. *Biol Psychiatry* 2007 Sep 15;62(6):593-9.

References

- (67) Walderhaug E, Lunde H, Nordvik JE, Landro NI, Refsum H, Magnusson A. Lowering of serotonin by rapid tryptophan depletion increases impulsiveness in normal individuals. *Psychopharmacology (Berl)* 2002 Dec;164(4):385-91.
- (68) Booi L, Swenne CA, Brosschot JF, Haffmans PM, Thayer JF, Van der Does AJ. Tryptophan Depletion Affects Heart Rate Variability and Impulsivity in Remitted Depressed Patients with a History of Suicidal Ideation. *Biol Psychiatry* 2006 Apr4.
- (69) Uchida S, Kitamoto A, Umeeda H, Nakagawa N, Masushige S, Kida S. Chronic reduction in dietary tryptophan leads to changes in the emotional response to stress in mice. *J Nutr Sci Vitaminol (Tokyo)* 2005 Jun;51(3):175-81.
- (70) Vergnes M, Kempf E. Tryptophan deprivation: effects on mouse-killing and reactivity in the rat. *Pharmacol Biochem Behav* 1981;14 Suppl 1:19-23.
- (71) Carlton PL, Advokat C. Attenuated habituation due to parachlorophenylalanine. *Pharmacol Biochem Behav* 1973 Nov;1(6):657-63.
- (72) Bidzinski A, Siemiatkowski M, Czlonkowska A, Tonderska A, Plaznik A. The effect of serotonin depletion on motor activity habituation, and [3H]muscimol binding in the rat hippocampus. *Eur J Pharmacol* 1998 Jul 17;353(1):5-12.
- (73) Walters JK, Davis M, Sheard MH. Tryptophan-free diet: effects on the acoustic startle reflex in rats. *Psychopharmacology (Berl)* 1979 Apr 11;62(2):103-9.
- (74) Williams JH, Meara JR, Azmitia EC. Effects of 5,7-dihydroxytryptamine injections in the fornix-fimbria on locomotor activity in photocell cages and the open field. *Behav Brain Res* 1990 Oct 30;40(1):37-44.
- (75) Deakin JF, File SE, Hyde JR, Macleod NK. Ascending 5-HT pathways and behavioural habituation. *Pharmacol Biochem Behav* 1979 May;10(5):687-94.
- (76) Davis M. Neural systems involved in fear-potentiated startle. *Ann N Y Acad Sci* 1989;563:165-83.
- (77) Tuomisto J, Mannisto P. Neurotransmitter regulation of anterior pituitary hormones. *Pharmacol Rev* 1985 Sep;37(3):249-332.
- (78) Porter RJ, Gallagher P, Watson S, Young AH. Corticosteroid-serotonin interactions in depression: a review of the human evidence. *Psychopharmacology (Berl)* 2004 Apr;173(1-2):1-17.
- (79) Di Sciullo A, Bluet-Pajot MT, Mounier F, Oliver C, Schmidt B, Kordon C. Changes in anterior pituitary hormone levels after serotonin 1A receptor stimulation. *Endocrinology* 1990 Aug;127(2):567-72.
- (80) Bagdy G, Calogero AE, Aulakh CS, Szemerédi K, Murphy DL. Long-term cortisol treatment impairs behavioral and neuroendocrine responses to 5-HT1 agonists in the rat. *Neuroendocrinology* 1989 Sep;50(3):241-7.
- (81) Morgan CJ, Badawy AA. Effects of a suppression test dose of dexamethasone on tryptophan metabolism and disposition in the rat. *Biol Psychiatry* 1989 Feb 1;25(3):359-62.
- (82) Martin CL, Duclos M, Aguerre S, Mormede P, Manier G, Chaouloff F. Corticotropic and serotonergic responses to acute stress with/without prior exercise training in different rat strains. *Acta Physiol Scand* 2000 Mar;168(3):421-30.
- (83) Meloni EG, Reedy CL, Cohen BM, Carlezon WA, Jr. Activation of raphe efferents to the

References

- medial prefrontal cortex by corticotropin-releasing factor: correlation with anxiety-like behavior. *Biol Psychiatry* 2008 May 1;63(9):832-9.
- (84) Price ML, Curtis AL, Kirby LG, Valentino RJ, Lucki I. Effects of corticotropin-releasing factor on brain serotonergic activity. *Neuropsychopharmacology* 1998 Jun;18(6):492-502.
- (85) Meijer OC, de Kloet ER. Corticosterone suppresses the expression of 5-HT1A receptor mRNA in rat dentate gyrus. *Eur J Pharmacol* 1994 Feb 15;266(3):255-61.
- (86) Mendelson SD, McEwen BS. Quantitative autoradiographic analyses of the time course and reversibility of corticosterone-induced decreases in binding at 5-HT1A receptors in rat forebrain. *Neuroendocrinology* 1992 Dec;56(6):881-8.
- (87) Russo S, Kema IP, Bosker F, Haavik J, Korf J. Tryptophan as an evolutionarily conserved signal to brain serotonin: Molecular evidence and psychiatric implications. *World J Biol Psychiatry* 2007 Sep 13;1-11.
- (88) Fuller RW. Serotonin receptors involved in regulation of pituitary-adrenocortical function in rats. *Behav Brain Res* 1996;73(1-2):215-9.
- (89) Maes M. Evidence for an immune response in major depression: a review and hypothesis. *Prog Neuropsychopharmacol Biol Psychiatry* 1995 Jan;19(1):11-38.
- (90) Lanfumey L, Mongeau R, Cohen-Salmon C, Hamon M. Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders. *Neurosci Biobehav Rev* 2008 Apr 29.
- (91) Nadeem HS, Attenburrow MJ, Cowen PJ. Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses. *Neuropsychopharmacology* 2004 Sep;29(9):1699-703.
- (92) Ahrens T, Frankhauser P, Lederbogen F, Deuschle M. Effect of single-dose sertraline on the hypothalamus-pituitary-adrenal system, autonomic nervous system, and platelet function. *J Clin Psychopharmacol* 2007 Dec;27(6):602-6.
- (93) Holsboer F, Liebl R, Hofschuster E. Repeated dexamethasone suppression test during depressive illness. Normalisation of test result compared with clinical improvement. *J Affect Disord* 1982 Jun;4(2):93-101.
- (94) Greden JF, Gardner R, King D, Grunhaus L, Carroll BJ, Kronfol Z. Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility. *Arch Gen Psychiatry* 1983 May;40(5):493-500.
- (95) Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. *Endocr Rev* 1996 Apr;17(2):187-205.
- (96) Brown GW, Harris TO. Depression and the serotonin transporter 5-HTTLPR polymorphism: A review and a hypothesis concerning gene-environment interaction. *J Affect Disord* 2008 Jun 3.
- (97) Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. *Science* 2003 Jul 18;301(5631):386-9.
- (98) Gillespie NA, Whitfield JB, Williams B, Heath AC, Martin NG. The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression. *Psychol Med* 2005 Jan;35(1):101-11.

References

- (99) Zalsman G, Huang YY, Oquendo MA, Burke AK, Hu XZ, Brent DA, et al. Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. *Am J Psychiatry* 2006 Sep;163(9):1588-93.
- (100) Ross SB, Renyl AL. Accumulation of tritiated 5-hydroxytryptamine in brain slices. *Life Sci* 1967 Jul 1;6(13):1407-15.
- (101) Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, et al. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. *Proc Natl Acad Sci U S A* 1993 Mar 15;90(6):2542-6.
- (102) Lesch KP, Wolozin BL, Murphy DL, Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. *J Neurochem* 1993 Jun;60(6):2319-22.
- (103) Greenberg BD, Tolliver TJ, Huang SJ, Li Q, Bengel D, Murphy DL. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. *Am J Med Genet* 1999 Feb 5;88(1):83-7.
- (104) Martel F, Monteiro R, Lemos C. Uptake of serotonin at the apical and basolateral membranes of human intestinal epithelial (Caco-2) cells occurs through the neuronal serotonin transporter (SERT). *J Pharmacol Exp Ther* 2003 Jul;306(1):355-62.
- (105) Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. *Am J Hum Genet* 2006 May;78(5):815-26.
- (106) Murphy DL, Li Q, Engel S, Wichems C, Andrews A, Lesch KP, et al. Genetic perspectives on the serotonin transporter. *Brain Res Bull* 2001 Nov 15;56(5):487-94.
- (107) Shaw K, Turner J, Del Mar C. Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis. *Aust N Z J Psychiatry* 2002 Aug;36(4):488-91.
- (108) Lacasse JR, Leo J. Serotonin and depression: a disconnect between the advertisements and the scientific literature. *PLoS Med* 2005 Dec;2(12):e392.
- (109) Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). *Int Clin Psychopharmacol* 1994 Mar;9 Suppl 1:19-26.
- (110) Jongasma ME. Serotonergic augmentation strategies; Possibilities and limitations. 2006.
- (111) Haddad PM. Antidepressant discontinuation syndromes. *Drug Saf* 2001;24(3):183-97.
- (112) Shelton RC. The nature of the discontinuation syndrome associated with antidepressant drugs. *J Clin Psychiatry* 2006;67 Suppl 4:3-7.
- (113) Sher L. Prevention of the serotonin reuptake inhibitor discontinuation syndrome. *Med Hypotheses* 2002 Jul;59(1):92-4.
- (114) Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. *Am Fam Physician* 2006 Aug 1;74(3):449-56.
- (115) Russo S, Boon JC, Kema IP, Willemse PH, Den Boer JA, Korf J, et al. Patients with carcinoid syndrome exhibit symptoms of aggressive impulse dysregulation. *Psychosom Med* 2004 May;66(3):422-5.
- (116) Russo S, Kema IP, Haagsma EB, Boon JC, Willemse PH, Den Boer JA, et al. Irritability

References

- rather than depression during interferon treatment is linked to increased tryptophan catabolism. *Psychosom Med* 2005 Sep;67(5):773-7.
- (117) Willner P, Mitchell PJ. The validity of animal models of predisposition to depression. *Behav Pharmacol* 2002 May;13(3):169-88.
- (118) Faraday MM. Rat sex and strain differences in responses to stress. *Physiol Behav* 2002 Apr 1;75(4):507-22.
- (119) Faraday MM, O'Donoghue VA, Grunberg NE. Effects of nicotine and stress on startle amplitude and sensory gating depend on rat strain and sex. *Pharmacol Biochem Behav* 1999 Feb;62(2):273-84.
- (120) Kant GJ, Leu JR, Anderson SM, Mougey EH. Effects of chronic stress on plasma corticosterone, ACTH and prolactin. *Physiol Behav* 1987;40(6):775-9.
- (121) Acri JB. Nicotine modulates effects of stress on acoustic startle reflexes in rats: dependence on dose, stressor and initial reactivity. *Psychopharmacology (Berl)* 1994 Nov;116(3):255-65.
- (122) Kant GJ, Lenox RH, Bunnell BN, Mougey EH, Pennington LL, Meyerhoff JL. Comparison of stress response in male and female rats: pituitary cyclic AMP and plasma prolactin, growth hormone and corticosterone. *Psychoneuroendocrinology* 1983;8(4):421-8.
- (123) Koch M. The neurobiology of startle. *Prog Neurobiol* 1999 Oct;59(2):107-28.
- (124) Leaton RN, Supple WF, Jr. Medial cerebellum and long-term habituation of acoustic startle in rats. *Behav Neurosci* 1991 Dec;105(6):804-16.
- (125) Davis M, Gendelman DS, Tischler MD, Gendelman PM. A primary acoustic startle circuit: lesion and stimulation studies. *J Neurosci* 1982 Jun;2(6):791-805.
- (126) Swerdlow NR, Braff DL, Taaid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. *Arch Gen Psychiatry* 1994 Feb;51(2):139-54.
- (127) Davis M, Strachan DI, Kass E. Excitatory and inhibitory effects of serotonin on sensorimotor reactivity measured with acoustic startle. *Science* 1980 Jul 25;209(4455):521-3.
- (128) Grillon C, Baas J. A review of the modulation of the startle reflex by affective states and its application in psychiatry. *Clin Neurophysiol* 2003 Sep;114(9):1557-79.
- (129) Davis M. Neural systems involved in fear and anxiety measured with fear-potentiated startle. *Am Psychol* 2006 Nov;61(8):741-56.
- (130) Geyer MA, Swerdlow NR. Measurement of startle response, prepulse inhibition, and habituation. In: Crawley JN, Skolnick P, editors. *Current protocols in neuroscience*. New York: Wiley; 1998. p. 8.7.1-8.7.15.
- (131) Harmer CJ, Reid CB, Ray MK, Goodwin GM, Cowen PJ. 5HT(3) antagonism abolishes the emotion potentiated startle effect in humans. *Psychopharmacology (Berl)* 2006 Mar 30.
- (132) Groves PM, Thompson RF. Habituation: a dual-process theory. *Psychol Rev* 1970 Sep;77(5):419-50.
- (133) Russo S, Kema IP, Fokkema MR, Boon JC, Willemse PH, de Vries EG, et al. Tryptophan as a link between psychopathology and somatic states. *Psychosom Med* 2003

References

- Jul;65(4):665-71.
- (134) Swain CP, Tavill AS, Neale G. Studies of tryptophan and albumin metabolism in a patient with carcinoid syndrome, pellagra, and hypoproteinemia. *Gastroenterology* 1976 Sep;71(3):484-9.
- (135) Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. *Annu Rev Biochem* 1998;67:227-64.
- (136) Menkes DB, MacDonald JA. Interferons, serotonin and neurotoxicity. *Psychol Med* 2000 Mar;30(2):259-68.
- (137) Van Gool AR, Fekkes D, Kruit WH, Mulder PG, Ten Hagen TL, Bannink M, et al. Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients. *Psychiatry Res* 2003 Jul 15;119(1-2):125-32.
- (138) Kamata M, Higuchi H, Yoshimoto M, Yoshida K, Shimizu T. Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. *Eur Neuropsychopharmacol* 2000 Mar;10(2):129-32.
- (139) Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological regulation by plasma neutral amino acids. *Science* 1972 Oct 27;178(59):414-6.
- (140) Capuron L, Ravaut A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. *Mol Psychiatry* 2002;7(5):468-73.
- (141) Van Gool AR, van Ojik HH, Kruit WH, Bannink M, Mulder PG, Eggermont AM, et al. Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations. *Anticancer Drugs* 2004 Jul;15(6):587-91.
- (142) Williams JW, Jr., Pignone M, Ramirez G, Perez SC. Identifying depression in primary care: a literature synthesis of case-finding instruments. *Gen Hosp Psychiatry* 2002 Jul;24(4):225-37.
- (143) Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: implicatons for therapy*1. *Journal of Affective Disorders* 2001 Jan;62(1-2):77-91.
- (144) Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, et al. A susceptibility gene for affective disorders and the response of the human amygdala. *Arch Gen Psychiatry* 2005 Feb;62(2):146-52.
- (145) Hsiao SY, Cherng CF, Yang YK, Yeh TL, Yu L. Prenatal bupropion exposure enhances the cocaine reward and stress susceptibility in adult mice. *Chin J Physiol* 2005 Dec 31;48(4):223-9.
- (146) Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. *Clin Chem* 1994 Feb;40(2):288-95.
- (147) Baldwin D, Rudge S. The role of serotonin in depression and anxiety. *Int Clin Psychopharmacol* 1995 Jan;9 Suppl 4:41-5.
- (148) Carroll BJ. The dexamethasone suppression test for melancholia. *Br J Psychiatry* 1982 Mar;140:292-304.
- (149) Holsboer F, Philipp M, Steiger A, Gerken A. Multiteroid analysis after DST in depressed patients--a controlled study. *J Affect Disord* 1986 May;10(3):241-9.

References

- (150) Modell S, Yassouridis A, Huber J, Holsboer F. Corticosteroid receptor function is decreased in depressed patients. *Neuroendocrinology* 1997 Mar;65(3):216-22.
- (151) Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. *Neuron* 2002 Mar 28;34(1):13-25.
- (152) Davis M. Neurochemical modulation of sensory-motor reactivity: acoustic and tactile startle reflexes. *Neurosci Biobehav Rev* 1980;4(2):241-63.
- (153) Conner RL, Stolk JM, Barchas JD, Levine S. Parachlorophenylalanine and habituation to repetitive auditory startle stimuli in rats. *Physiol Behav* 1970 Nov;5(11):1215-9.
- (154) Dringenberg HC, Hargreaves EL, Baker GB, Cooley RK, Vanderwolf CH. p-chlorophenylalanine-induced serotonin depletion: reduction in exploratory locomotion but no obvious sensory-motor deficits. *Behav Brain Res* 1995 Jun;68(2):229-37.
- (155) Prinssen EP, Assie MB, Koek W, Kleven MS. Depletion of 5-HT disrupts prepulse inhibition in rats: dependence on the magnitude of depletion, and reversal by a 5-HT precursor. *Neuropsychopharmacology* 2002 Mar;26(3):340-7.
- (156) Fletcher PJ, Selhi ZF, Azampanah A, Sills TL. Reduced brain serotonin activity disrupts prepulse inhibition of the acoustic startle reflex. Effects of 5,7-dihydroxytryptamine and p-chlorophenylalanine. *Neuropsychopharmacology* 2001 Apr;24(4):399-409.
- (157) Weber M, Schnitzler HU, Schmid S. Synaptic plasticity in the acoustic startle pathway: the neuronal basis for short-term habituation? *Eur J Neurosci* 2002 Oct;16(7):1325-32.
- (158) Sheng M, Greenberg ME. The regulation and function of c-fos and other immediate early genes in the nervous system. *Neuron* 1990 Apr;4(4):477-85.
- (159) Sagar SM, Sharp FR, Curran T. Expression of c-fos protein in brain: metabolic mapping at the cellular level. *Science* 1988 Jun 3;240(4857):1328-31.
- (160) Zylan KD, Brown SD. Effect of stress and food variety on food intake in male and female rats. *Physiol Behav* 1996 Jan;59(1):165-9.
- (161) Sharp FR, Sagar SM, Hicks K, Lowenstein D, Hisanaga K. c-fos mRNA, Fos, and Fos-related antigen induction by hypertonic saline and stress. *J Neurosci* 1991 Aug;11(8):2321-31.
- (162) van der Stelt HM, Broersen LM, Olivier B, Westenberg HG. Effects of dietary tryptophan variations on extracellular serotonin in the dorsal hippocampus of rats. *Psychopharmacology (Berl)* 2004 Mar;172(2):137-44.
- (163) Imre G, Fokkema DS, Den Boer JA, Ter Horst GJ. Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. *Brain Res Bull* 2006 Apr 14;69(3):338-45.
- (164) Davis M, Sheard MH. Habituation and sensitization of the rat startle response: effects of raphe lesions. *Physiol Behav* 1974 Mar;12(3):425-31.
- (165) Fluttert M, Dalm S, Oitzl MS. A refined method for sequential blood sampling by tail incision in rats. *Lab Anim* 2000 Oct;34(4):372-8.
- (166) Kema IP, Meijer WG, Meiborg G, Ooms B, Willemse PH, de Vries EG. Profiling of tryptophan-related plasma indoles in patients with carcinoid tumors by automated, on-line, solid-phase extraction and HPLC with fluorescence detection. *Clin Chem* 2001 Oct;47(10):1811-20.

References

- (167) Moore S, Spackman DH, Stein WH. Automatic recording apparatus for use in the chromatography of amino acids. *Fed Proc* 1958 Dec;17(4):1107-15.
- (168) Westenbroek C, Ter Horst GJ, Roos MH, Kuipers SD, Trentani A, Den Boer JA. Gender-specific effects of social housing in rats after chronic mild stress exposure. *Prog Neuropsychopharmacol Biol Psychiatry* 2003 Feb;27(1):21-30.
- (169) Nyakas C, Buwalda B, Kramers RJ, Traber J, Luiten PG. Postnatal development of hippocampal and neocortical cholinergic and serotonergic innervation in rat: effects of nitrite-induced prenatal hypoxia and nimodipine treatment. *Neuroscience* 1994 Apr;59(3):541-59.
- (170) Bandler R, Keay KA, Floyd N, Price J. Central circuits mediating patterned autonomic activity during active vs. passive emotional coping. *Brain Res Bull* 2000 Sep 1;53(1):95-104.
- (171) Morgane PJ, Galler JR, Mokler DJ. A review of systems and networks of the limbic forebrain/limbic midbrain. *Prog Neurobiol* 2005 Feb;75(2):143-60.
- (172) Pezze MA, Heidbreder CA, Feldon J, Murphy CA. Selective responding of nucleus accumbens core and shell dopamine to aversively conditioned contextual and discrete stimuli. *Neuroscience* 2001;108(1):91-102.
- (173) Carta M, Fadda F, Stancampiano R. Tryptophan-deficient diet increases the neurochemical and behavioral response to amphetamine. *Brain Res* 2006 May 23.
- (174) Fechter LD, Ison JR. The inhibition of the acoustic startle reaction in rats by food and water deprivation. *Learn Motiv* 1972;3:109-24.
- (175) Yunger LM, Harvey JA. Effect of lesions in the medial forebrain bundle on three measures of pain sensitivity and noise-elicited startle. *J Comp Physiol Psychol* 1973 May;83(2):173-83.
- (176) Patel NV, Finch CE. The glucocorticoid paradox of caloric restriction in slowing brain aging. *Neurobiol Aging* 2002 Sep;23(5):707-17.
- (177) Keller-Wood ME, Dallman MF. Corticosteroid inhibition of ACTH secretion. *Endocr Rev* 1984;5(1):1-24.
- (178) Benarroch EE. Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system. *Mayo Clin Proc* 2005 Oct;80(10):1326-38.
- (179) Karege F, Widmer J, Bovier P, Gaillard JM. Platelet serotonin and plasma tryptophan in depressed patients: effect of drug treatment and clinical outcome. *Neuropsychopharmacology* 1994 May;10(3):207-14.
- (180) Young SN. The use of diet and dietary components in the study of factors controlling affect in humans: a review. *J Psychiatry Neurosci* 1993 Nov;18(5):235-44.
- (181) Franklin M, Cowen PJ. Effect of a low tryptophan diet on the prolactin responses to the 5-HT_{2A} agonist DOI in the rat. *Pharmacopsychiatry* 2001 Jul;34(4):147-9.
- (182) Tanke MA, Alserda E, Doornbos B, van der Most PJ, Goeman K, Postema F, et al. Low tryptophan diet increases stress-sensitivity, but does not affect habituation in rats. *Neurochem Int* 2008 Jan;52(1-2):272-81.
- (183) Phillips MA, Oxtoby EK, Langley RW, Bradshaw CM, Szabadi E. Effects of acute tryptophan depletion on prepulse inhibition of the acoustic startle (eyeblink) response and the N1/P2 auditory evoked response in man. *J Psychopharmacol* 2000;14(3):258-

References

- 65.
- (184) Bosker FJ, de Winter TY, Klompmakers AA, Westenberg HG. Flesinoxan dose-dependently reduces extracellular 5-hydroxytryptamine (5-HT) in rat median raphe and dorsal hippocampus through activation of 5-HT_{1A} receptors. *J Neurochem* 1996 Jun;66(6):2546-55.
- (185) Padich RA, McCloskey TC, Kehne JH. 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT_{2A} antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. *Psychopharmacology (Berl)* 1996 Mar;124(1-2):107-16.
- (186) Sipes TA, Geyer MA. 8-OH-DPAT disruption of prepulse inhibition in rats: reversal with (+)WAY 100,135 and localization of site of action. *Psychopharmacology (Berl)* 1995 Jan;117(1):41-8.
- (187) Sipes TA, Geyer MA. Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. *Neuropharmacology* 1994 Mar;33(3-4):441-8.
- (188) Sipes TE, Geyer MA. Functional behavioral homology between rat 5-HT_{1B} and guinea pig 5-HT_{1D} receptors in the modulation of prepulse inhibition of startle. *Psychopharmacology (Berl)* 1996 Jun;125(3):231-7.
- (189) Rigdon GC, Weatherspoon JK. 5-Hydroxytryptamine 1a receptor agonists block prepulse inhibition of acoustic startle reflex. *J Pharmacol Exp Ther* 1992 Nov;263(2):486-93.
- (190) Nanry KP, Tilson HA. The role of 5HT_{1A} receptors in the modulation of the acoustic startle reflex in rats. *Psychopharmacology (Berl)* 1989;97(4):507-13.
- (191) Li XB, Inoue T, Hashimoto S, Koyama T. Effect of chronic administration of flesinoxan and fluvoxamine on freezing behavior induced by conditioned fear. *Eur J Pharmacol* 2001 Aug 3;425(1):43-50.
- (192) Overstreet DH, Kralic JE, Morrow AL, Ma ZZ, Zhang YW, Lee DY. NPI-031G (puerarin) reduces anxiogenic effects of alcohol withdrawal or benzodiazepine inverse or 5-HT_{2C} agonists. *Pharmacol Biochem Behav* 2003 Jun;75(3):619-25.
- (193) Millan MJ, Brocco M, Gobert A, Dorey G, Casara P, Dekeyne A. Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. *Neuropsychopharmacology* 2001 Oct;25(4):585-600.
- (194) Body S, Cheung TH, Bezzina G, Asgari K, Fone KC, Glennon JC, et al. Effects of d-amphetamine and DOI (2,5-dimethoxy-4-iodoamphetamine) on timing behavior: interaction between D1 and 5-HT_{2A} receptors. *Psychopharmacology (Berl)* 2006 Dec;189(3):331-43.
- (195) Asgari K, Body S, Bak VK, Zhang ZQ, Rickard JF, Glennon JC, et al. Effects of 5-HT_{2A} receptor stimulation on the discrimination of durations by rats. *Behav Pharmacol* 2006 Feb;17(1):51-9.
- (196) Body S, Asgari K, Rickard JF, Zhang Z, Fone KC, Bradshaw CM, et al. Effects of quipazine and m-chlorophenylbiguanide (m-CPBG) on temporal differentiation: evidence for the involvement of 5-HT_{2A} but not 5-HT₃ receptors in interval timing behaviour. *Psychopharmacology (Berl)* 2005 Sep;181(2):289-98.
- (197) Ji SP, Zhang Y, Van CJ, Jiang W, Liao M, Li L, et al. Disruption of PTEN coupling with 5-

- HT2C receptors suppresses behavioral responses induced by drugs of abuse. *Nat Med* 2006 Mar;12(3):324-9.
- (198) Simansky KJ. Serotonergic control of the organization of feeding and satiety. *Behav Brain Res* 1996;73(1-2):37-42.
- (199) Svensson L, Ahlenius S. Enhancement by the putative 5-HT receptor agonist 8-OH-2-(di-n-propylamino)tetralin of the acoustic startle response in the rat. *Psychopharmacology (Berl)* 1983;79(2-3):104-7.
- (200) Farid M, Martinez ZA, Geyer MA, Swerdlow NR. Regulation of sensorimotor gating of the startle reflex by serotonin 2A receptors. Ontogeny and strain differences. *Neuropsychopharmacology* 2000 Dec;23(6):623-32.
- (201) Harrell AV, Allan AM. Improvements in hippocampal-dependent learning and decremental attention in 5-HT(3) receptor overexpressing mice. *Learn Mem* 2003 Sep;10(5):410-9.
- (202) Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. *J Pharmacol Exp Ther* 2008 May;325(2):577-87.
- (203) Ballesteros J, Callado LF. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. *J Affect Disord* 2004 Apr;79(1-3):137-47.
- (204) Sharp SC, Hellings JA. Efficacy and safety of selective serotonin reuptake inhibitors in the treatment of depression in children and adolescents: practitioner review. *Clin Drug Investig* 2006;26(5):247-55.
- (205) Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. *Depress Anxiety* 1998;7 Suppl 1:11-7.
- (206) Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. *PLoS Med* 2008 Feb;5(2):e45.
- (207) Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. *BMJ* 2005 Feb 19;330(7488):396.
- (208) Cohen D. Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned? *Psychother Psychosom* 2007;76(1):5-14.
- (209) Javors MA, Houston JP, Tekell JL, Brannan SK, Frazer A. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. *Int J Neuropsychopharmacol* 2000 Sep;3(3):229-35.
- (210) Lee NS, Wagner GC, Trout JR, Fisher H. Fenfluramine-induced behavior changes in rats prefer serotonin-altering amounts of tryptophan and pyridoxine. *Pharmacol Biochem Behav* 1988 Mar;29(3):565-71.
- (211) Linkswiler H. Biochemical and physiological changes in vitamin B6 deficiency. *Am J Clin Nutr* 1967 Jun;20(6):547-61.
- (212) Tzvetkov MV, Brockmoller J, Roots I, Kirchheiner J. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. *Pharmacogenet Genomics* 2008 Jun;18(6):495-506.

References

- (213) Demyttenaere K, Haddad P. Compliance with antidepressant therapy and antidepressant discontinuation symptoms. *Acta Psychiatr Scand Suppl* 2000;403:50-6.
- (214) FDA Public Health Advisory. Suicidality in children and adolescents being treated with antidepressant medications. FDA 2004, www.fda.gov/cder/drug/antidepressants/SSRIPHA200410.htm
- (215) Blier P, de MC, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. *J Clin Psychopharmacol* 1987 Dec;7(6 Suppl):24S-35S.
- (216) Wagner GC, Montero D, Martensson B, Siwers B, Asberg M. Effects of fluoxetine treatment of platelet 3H-imipramine binding, 5-HT uptake and 5-HT content in major depressive disorder. *J Affect Disord* 1990 Oct;20(2):101-13.
- (217) Asberg M, Bertilsson L, Martensson B, Scalia-Tomba GP, Thoren P, Traskman-Bendz L. CSF monoamine metabolites in melancholia. *Acta Psychiatr Scand* 1984 Mar;69(3):201-19.
- (218) Neumaier JF, Root DC, Hamblin MW. Chronic fluoxetine reduces serotonin transporter mRNA and 5-HT1B mRNA in a sequential manner in the rat dorsal raphe nucleus. *Neuropsychopharmacology* 1996 Nov;15(5):515-22.
- (219) Veenema AH, Cremers TI, Jongsma ME, Steenbergen PJ, De Boer SF, Koolhaas JM. Differences in the effects of 5-HT(1A) receptor agonists on forced swimming behavior and brain 5-HT metabolism between low and high aggressive mice. *Psychopharmacology (Berl)* 2005 Mar;178(2-3):151-60.
- (220) Cremers TI, Spoelstra EN, de BP, Bosker FJ, Mork A, Den Boer JA, et al. Desensitisation of 5-HT autoreceptors upon pharmacokinetically monitored chronic treatment with citalopram. *Eur J Pharmacol* 2000 Jun 2;397(2-3):351-7.
- (221) Baumann P. Clinical pharmacokinetics of citalopram and other selective serotonergic reuptake inhibitors (SSRI). *Int Clin Psychopharmacol* 1992 Jun;6 Suppl 5:13-20.
- (222) Stenfors C, Ross SB. Evidence for involvement of 5-hydroxytryptamine(1B) autoreceptors in the enhancement of serotonin turnover in the mouse brain following repeated treatment with fluoxetine. *Life Sci* 2002 Nov 1;71(24):2867-80.
- (223) Esteban S, Llado J, Sastre-Coll A, Garcia-Sevilla JA. Activation and desensitization by cyclic antidepressant drugs of alpha2-autoreceptors, alpha2-heteroreceptors and 5-HT1A-autoreceptors regulating monoamine synthesis in the rat brain in vivo. *Naunyn Schmiedebergs Arch Pharmacol* 1999 Aug;360(2):135-43.
- (224) Moret C, Briley M. Effect of antidepressant drugs on monoamine synthesis in brain in vivo. *Neuropharmacology* 1992 Jul;31(7):679-84.
- (225) Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. *Arch Gen Psychiatry* 1990 May;47(5):411-8.
- (226) Hendricks TJ, Fyodorov DV, Wegman LJ, Lelutiu NB, Pehek EA, Yamamoto B, et al. Pet-1 ETS gene plays a critical role in 5-HT neuron development and is required for normal anxiety-like and aggressive behavior. *Neuron* 2003 Jan 23;37(2):233-47.
- (227) Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical

References

- management and additional research. *J Clin Psychiatry* 2006;67 Suppl 4:27-30.
- (228) Eaddy MT, Druss BG, Sarnes MW, Regan TS, Frankum LE. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy--results from a managed care administrative claims database. *J Manag Care Pharm* 2005 Mar;11(2):145-50.
- (229) Demyttenaere K, Mesters P, Boulanger B, Dewe W, Delsemme MH, Gregoire J, et al. Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine. *J Affect Disord* 2001 Aug;65(3):243-52.
- (230) Blier P, Tremblay P. Physiologic mechanisms underlying the antidepressant discontinuation syndrome. *J Clin Psychiatry* 2006;67 Suppl 4:8-13.
- (231) Andres AH, Rao ML, Ostrowitzki S, Entzian W. Human brain cortex and platelet serotonin₂ receptor binding properties and their regulation by endogenous serotonin. *Life Sci* 1993;52(3):313-21.
- (232) Looper KJ. Potential medical and surgical complications of serotonergic antidepressant medications. *Psychosomatics* 2007 Jan;48(1):1-9.
- (233) Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. *Clin Pharmacol Ther* 2000 Oct;68(4):435-42.
- (234) Epperson CN, Jatlow PI, Czarkowski K, Anderson GM. Maternal fluoxetine treatment in the postpartum period: effects on platelet serotonin and plasma drug levels in breastfeeding mother-infant pairs. *Pediatrics* 2003 Nov;112(5):e425.
- (235) Norra C, Becker S, Herpertz SC, Kunert HJ. Effects of experimental acute tryptophan depletion on acoustic startle response in females. *Eur Arch Psychiatry Clin Neurosci* 2007 Sep 27.
- (236) Grillon C, Levenson J, Pine DS. A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study. *Neuropsychopharmacology* 2007 Jan;32(1):225-31.
- (237) Martinez DL, Geyer MA. Characterization of the disruptions of prepulse inhibition and habituation of startle induced by alpha-ethyltryptamine. *Neuropsychopharmacology* 1997 Mar;16(3):246-55.
- (238) Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. *Am J Psychiatry* 2004 Jul;161(7):1256-63.
- (239) Jensen KS, Oranje B, Wienberg M, Glenthøj BY. The effects of increased central serotonergic activity on prepulse inhibition and habituation of the human startle response. *Neuropsychopharmacology* 2007 Oct;32(10):2117-24.
- (240) Oyehaug E, Ostensen ET, Salvesen B. Determination of the antidepressant agent citalopram and metabolites in plasma by liquid chromatography with fluorescence detection. *J Chromatogr* 1982 Jan 8;227(1):129-35.
- (241) Fredricson OK. Kinetics of citalopram in test animals; drug exposure in safety studies. *Prog Neuropsychopharmacol Biol Psychiatry* 1982;6(3):297-309.
- (242) Bjork JM, Gaytan O, Patt N, Swann AC, Dafny N. Behavioral tolerance to and withdrawal from multiple fluoxetine administration. *Int J Neurosci* 1998 Apr;93(3-4):163-79.

References

- (243) Pouzet B, Andersen MP, Hogg S. Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats. *Psychopharmacology (Berl)* 2005 Feb;178(1):9-16.
- (244) Geyer MA, Tapson GS. Habituation of tactile startle is altered by drugs acting on serotonin-2 receptors. *Neuropsychopharmacology* 1988 May;1(2):135-47.
- (245) Liechti ME, Geyer MA, Hell D, Vollenweider FX. Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. *Neuropsychopharmacology* 2001 Mar;24(3):240-52.
- (246) Healy D. Did regulators fail over selective serotonin reuptake inhibitors? *BMJ* 2006 Jul 8;333(7558):92-5.
- (247) Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. *N Engl J Med* 2007 Jun 7;356(23):2343-6.
- (248) Healy D, Aldred G. Antidepressant drug use & the risk of suicide. *Int Rev Psychiatry* 2005 Jun;17(3):163-72.
- (249) Johnson EO, Kamilaris TC, Chrousos GP, Gold PW. Mechanisms of stress: a dynamic overview of hormonal and behavioral homeostasis. *Neurosci Biobehav Rev* 1992;16(2):115-30.
- (250) Burchfield SR. The stress response: a new perspective. *Psychosom Med* 1979 Dec;41(8):661-72.
- (251) Het S, Ramlow G, Wolf OT. A meta-analytic review of the effects of acute cortisol administration on human memory. *Psychoneuroendocrinology* 2005 Sep;30(8):771-84.
- (252) Belanoff JK, Gross K, Yager A, Schatzberg AF. Corticosteroids and cognition. *J Psychiatr Res* 2001 May;35(3):127-45.
- (253) Sonino N, Fava GA. Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment. *CNS Drugs* 2001;15(5):361-73.
- (254) Meyer JS, Micco DJ, Stephenson BS, Krey LC, McEwen BS. Subcutaneous implantation method for chronic glucocorticoid replacement therapy. *Physiol Behav* 1979 May;22(5):867-70.
- (255) Akana SF, Scribner KA, Bradbury MJ, Strack AM, Walker CD, Dallman MF. Feedback sensitivity of the rat hypothalamo-pituitary-adrenal axis and its capacity to adjust to exogenous corticosterone. *Endocrinology* 1992 Aug;131(2):585-94.
- (256) Akana SF, Cascio CS, Shinsako J, Dallman MF. Corticosterone: narrow range required for normal body and thymus weight and ACTH. *Am J Physiol* 1985 Nov;249(5 Pt 2):R527-R532.
- (257) Bush VL, Middlemiss DN, Marsden CA, Fone KC. Implantation of a slow release corticosterone pellet induces long-term alterations in serotonergic neurochemistry in the rat brain. *J Neuroendocrinol* 2003 Jun;15(6):607-13.
- (258) Young EA, Kwak SP, Kottak J. Negative feedback regulation following administration of chronic exogenous corticosterone. *J Neuroendocrinol* 1995 Jan;7(1):37-45.
- (259) Oka T, Oka K, Hori T. Mechanisms and mediators of psychological stress-induced rise in core temperature. *Psychosom Med* 2001 May;63(3):476-86.
- (260) Briese E. Normal body temperature of rats: the setpoint controversy. *Neurosci Biobehav Rev* 1998 May;22(3):427-36.
- (261) Dal Zotto S, Marti O, Armario A. Glucocorticoids are involved in the long-term effects of

References

- a single immobilization stress on the hypothalamic-pituitary-adrenal axis. *Psychoneuroendocrinology* 2003 Nov;28(8):992-1009.
- (262) van den Buuse M, Morris M, Chavez C, Martin S, Wang J. Effect of adrenalectomy and corticosterone replacement on prepulse inhibition and locomotor activity in mice. *Br J Pharmacol* 2004 Jun;142(3):543-50.
- (263) Buchanan TW, Brechtel A, Sollers JJ, Lovallo WR. Exogenous cortisol exerts effects on the startle reflex independent of emotional modulation. *Pharmacol Biochem Behav* 2001 Feb;68(2):203-10.
- (264) Yntema OP, Korf J. Transient suppression by stress of haloperidol induced catalepsy by the activation of the adrenal medulla. *Psychopharmacology (Berl)* 1987;91(1):131-4.
- (265) Chopde CT, Hote MS, Mandhane SN, Muthal AV. Glucocorticoids attenuate haloperidol-induced catalepsy through adrenal catecholamines. *J Neural Transm Gen Sect* 1995;102(1):47-54.
- (266) Morrow LE, McClellan JL, Conn CA, Kluger MJ. Glucocorticoids alter fever and IL-6 responses to psychological stress and to lipopolysaccharide. *Am J Physiol* 1993 May;264(5 Pt 2):R1010-R1016.
- (267) Watts AG, Sanchez-Watts G. Interactions between heterotypic stressors and corticosterone reveal integrative mechanisms for controlling corticotropin-releasing hormone gene expression in the rat paraventricular nucleus. *J Neurosci* 2002 Jul 15;22(14):6282-9.
- (268) Liang KC, Melia KR, Miserendino MJ, Falls WA, Campeau S, Davis M. Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex. *J Neurosci* 1992 Jun;12(6):2303-12.
- (269) Koob GF, Heinrichs SC, Pich EM, Menzaghi F, Baldwin H, Miczek K, et al. The role of corticotropin-releasing factor in behavioural responses to stress. *Ciba Found Symp* 1993;172:277-89.
- (270) Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? *Brain Res Brain Res Rev* 1990 May;15(2):71-100.
- (271) Kema IP, de Vries EG, Slooff MJ, Biesma B, Muskiet FA. Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. *Clin Chem* 1994 Jan;40(1):86-95.
- (272) van der Horst-Schrivers AN, Wymenga AN, Links TP, Willemse PH, Kema IP, de Vries EG. Complications of midgut carcinoid tumors and carcinoid syndrome. *Neuroendocrinology* 2004;80 Suppl 1:28-32.
- (273) Goedert M, Otten U, Suda K, Heitz PU, Stalder GA, Obrecht JP, et al. Dopamine, norepinephrine and serotonin production by an intestinal carcinoid tumor. *Cancer* 1980 Jan 1;45(1):104-7.
- (274) Holdcroft A. Hormones and the gut. *Br J Anaesth* 2000 Jul;85(1):58-68.
- (275) Vielhaber K, Riemann D, Feige B, Kuelz A, Kirschbaum C, Voderholzer U. Impact of experimentally induced serotonin deficiency by tryptophan depletion on saliva cortisol concentrations. *Pharmacopsychiatry* 2005 Mar;38(2):87-94.
- (276) Parker KJ, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercortisolism in major depression. *Horm Behav* 2003 Jan;43(1):60-6.

References

- (277) Chaouloff F. Serotonin, stress and corticoids. *J Psychopharmacol* 2000 Jun;14(2):139-51.
- (278) Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. *Endocr Rev* 1996 Apr;17(2):187-205.
- (279) Meijer WG, Kema IP, Volmer M, Willemse PH, de Vries EG. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. *Clin Chem* 2000 Oct;46(10):1588-96.
- (280) Mulder EJ, Oosterloo-Duinkerken A, Anderson GM, de Vries EG, Minderaa RB, Kema IP. Automated on-line solid-phase extraction coupled with HPLC for measurement of 5-hydroxyindole-3-acetic acid in urine. *Clin Chem* 2005 Sep;51(9):1698-703.
- (281) Kema IP, de Vries EG, Muskiet FA. Clinical chemistry of serotonin and metabolites. *J Chromatogr B Biomed Sci Appl* 2000 Sep 29;747(1-2):33-48.
- (282) Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. *Nat Med* 2003 Oct;9(10):1269-74.
- (283) Attia E, Wolk S, Cooper T, Glasofer D, Walsh BT. Plasma tryptophan during weight restoration in patients with anorexia nervosa. *Biol Psychiatry* 2005 Mar 15;57(6):674-8.
- (284) Kema IP, de Vries EG, Schellings AM, Postmus PE, Muskiet FA. Improved diagnosis of carcinoid tumors by measurement of platelet serotonin. *Clin Chem* 1992 Apr;38(4):534-40.
- (285) Tyrka AR, Carpenter LL, McDougale CJ, Kirwin PD, Owens MJ, Nemeroff CB, et al. Increased cerebrospinal fluid corticotropin-releasing factor concentrations during tryptophan depletion in healthy adults. *Biol Psychiatry* 2004 Oct 1;56(7):531-4.
- (286) Porter RJ, Gallagher P, O'Brien JT. Effects of rapid tryptophan depletion on salivary cortisol in older people recovered from depression, and the healthy elderly. *J Psychopharmacol* 2006 Mar 13.
- (287) Sobczak S, Honig A, Nicolson NA, Riedel WJ. Effects of acute tryptophan depletion on mood and cortisol release in first-degree relatives of type I and type II bipolar patients and healthy matched controls. *Neuropsychopharmacology* 2002 Nov;27(5):834-42.
- (288) Porter RJ, Marshall EF, O'Brien JT. Effects of rapid tryptophan depletion on salivary and plasma cortisol in Alzheimer's disease and the healthy elderly. *J Psychopharmacol* 2002 Mar;16(1):73-8.
- (289) D'Souza DN, Zhang Y, Garcia F, Battaglia G, Van de Kar LD. Fluoxetine-induced changes in body weight and 5-HT1A receptor-mediated hormone secretion in rats on a tryptophan-deficient diet. *Am J Physiol Regul Integr Comp Physiol* 2004 Feb;286(2):R390-R397.
- (290) Koopmans SJ, Ruis M, Dekker R, van Diepen H, Korte M, Mroz Z. Surplus dietary tryptophan reduces plasma cortisol and noradrenaline concentrations and enhances recovery after social stress in pigs. *Physiol Behav* 2005 Jul 21;85(4):469-78.
- (291) Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. *Hepatology* 1997 Sep;26(3 Suppl 1):112S-21S.
- (292) Schafer A, Wittchen HU, Seufert J, Kraus MR. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. *Int J Methods Psychiatr Res* 2007;16(4):186-201.
- (293) Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha

- therapy. *Pharm World Sci* 2005 Dec;27(6):423-31.
- (294) Schaefer M, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Schmidt F, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. *Prog Neuropsychopharmacol Biol Psychiatry* 2002 May;26(4):731-46.
- (295) Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. *Am J Psychiatry* 2000 Jun;157(6):867-76.
- (296) Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. *J Clin Oncol* 2000 Jun;18(11):2316-26.
- (297) Lotrich FE, Rabinovitz M, Gironda P, Pollock BG. Depression following pegylated interferon-alpha: Characteristics and vulnerability. *J Psychosom Res* 2007 Aug;63(2):131-5.
- (298) Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. *CNS Drugs* 2005;19(2):105-23.
- (299) Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. *Lancet* 2007 Dec 22;370(9605):2103-11.
- (300) Asnis GM, De La GR. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. *J Clin Gastroenterol* 2006 Apr;40(4):322-35.
- (301) Van Gool AR, Kruit WH, Engels FK, Stoter G, Bannink M, Eggermont AM. Neuropsychiatric side effects of interferon-alfa therapy. *Pharm World Sci* 2003 Feb;25(1):11-20.
- (302) Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. *J Clin Psychiatry* 2003 Jun;64(6):708-14.
- (303) Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. *Psychiatry Res* 2001 Dec 15;105(1-2):45-55.
- (304) Menkes DB, MacDonald JA. Interferons, serotonin and neurotoxicity. *Psychol Med* 2000 Mar;30(2):259-68.
- (305) Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. *N Engl J Med* 2001 Mar 29;344(13):961-6.
- (306) Menkes DB, MacDonald JA. Interferons, serotonin and neurotoxicity. *Psychol Med* 2000 Mar;30(2):259-68.
- (307) Nemeroff CB. Recent advances in the neurobiology of depression. *Psychopharmacol Bull* 2002;36 Suppl 2:6-23.
- (308) Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. *J Clin Psychiatry* 2000;61 Suppl 6:4-6.
- (309) Drummond PD. Tryptophan depletion increases nausea, headache and photophobia in migraine sufferers. *Cephalalgia* 2006 Oct;26(10):1225-33.

References

- (310) Kilkens TO, Honig A, van Nieuwenhoven MA, Riedel WJ, Brummer RJ. Acute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controls. *Gut* 2004 Dec;53(12):1794-800.
- (311) Dougherty DM, Moeller FG, Bjork JM, Marsh DM. Plasma L-tryptophan depletion and aggression. *Adv Exp Med Biol* 1999;467:57-65.
- (312) Bell CJ, Hood SD, Nutt DJ. Acute tryptophan depletion. Part II: clinical effects and implications. *Aust N Z J Psychiatry* 2005 Jul;39(7):565-74.
- (313) Flory JD, Newcorn JH, Miller C, Harty S, Halperin JM. Serotonergic function in children with attention-deficit hyperactivity disorder: relationship to later antisocial personality disorder. *Br J Psychiatry* 2007 May;190:410-4.
- (314) Young SN, Leyton M. The role of serotonin in human mood and social interaction. Insight from altered tryptophan levels. *Pharmacol Biochem Behav* 2002 Apr;71(4):857-65.
- (315) aan het Rot M, Moskowitz DS, Pinard G, Young SN. Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals. *J Psychiatry Neurosci* 2006 Jul;31(4):253-62.
- (316) Bannink M, Kruit WH, Van Gool AR, Sleijfer S, van der HB, Eggermont AM, et al. Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated. *Psychosomatics* 2008 Jan;49(1):56-63.
- (317) Bannink M, Fekkes D, Van Gool AR, Kruit WH, Sleijfer S, van der HB, et al. Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects. *Neuropsychobiology* 2007;55(3-4):225-31.
- (318) Fekkes D, van Dalen A, Edelman M, Voskuilen A. Validation of the determination of amino acids in plasma by high-performance liquid chromatography using automated pre-column derivatization with o-phthaldialdehyde. *J Chromatogr B Biomed Appl* 1995 Jul 21;669(2):177-86.
- (319) Derogatis L, Cleary P. Confirmation of the dimensional structure of the SCL-90: a study in construct validity. *J Cons Psychol* 21977;33:981-9.
- (320) Arrindell WA, Ettema H. Handleiding bij een multidimensionale psychopathologie-indicator. Lisse: Swets & Zeitlinger; 2003.
- (321) Bryk AS, Raudenbush SW. Application of hierarchical linear models tot assessing change. *Psychol Bull* 1987;101:147-58.
- (322) Cohen J. Statistical power analysis for the behavioral science. 2nd ed. Lawrence Earlbaum Associates; 1988.
- (323) Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. *Biol Psychiatry* 2003 Nov 1;54(9):906-14.
- (324) Wichers MC, Koek GH, Robaey G, Verkerk R, Scharpe S, Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. *Mol Psychiatry* 2005 Jun;10(6):538-44.
- (325) Neumeister A, Nugent AC, Waldeck T, Geraci M, Schwarz M, Bonne O, et al. Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. *Arch Gen Psychiatry* 2004 Aug;61(8):765-73.
- (326) Kraus MR, Al Taie O, Schafer A, Pfersdorff M, Lesch KP, Scheurlen M. Serotonin-1A

References

- receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. *Gastroenterology* 2007 Apr;132(4):1279-86.
- (327) Russo S, Boon JC, Korf J, Haagsma EB. Mirtazapine for the treatment of interferon-induced psychopathology. *Gen Hosp Psychiatry* 2003 Nov;25(6):497.
- (328) Doornbos B, Fekkes D, Tanke MA, De JP, Korf J. Sequential serotonin and noradrenalin associated processes involved in postpartum blues. *Prog Neuropsychopharmacol Biol Psychiatry* 2008 Jul 1;32(5):1320-5.
- (329) Menkes DB, MacDonald JA. Interferons, serotonin and neurotoxicity. *Psychol Med* 2000 Mar;30(2):259-68.
- (330) Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. *Int J Neuropsychopharmacol* 2002 Dec;5(4):375-88.
- (331) Arango V, Huang YY, Underwood MD, Mann JJ. Genetics of the serotonergic system in suicidal behavior. *J Psychiatr Res* 2003 Sep;37(5):375-86.
- (332) Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. *Science* 1996 Nov 29;274(5292):1527-31.
- (333) Parsey RV, Hastings RS, Oquendo MA, Huang YY, Simpson N, Arcement J, et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. *Am J Psychiatry* 2006 Jan;163(1):52-8.
- (334) Little KY, McLaughlin DP, Zhang L, Livermore CS, Dalack GW, McFinton PR, et al. Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. *Am J Psychiatry* 1998 Feb;155(2):207-13.
- (335) Levinson DF. The genetics of depression: a review. *Biol Psychiatry* 2006 Jul 15;60(2):84-92.
- (336) Lotrich FE, Pollock BG. Meta-analysis of serotonin transporter polymorphisms and affective disorders. *Psychiatr Genet* 2004 Sep;14(3):121-9.
- (337) Lasky-Su JA, Faraone SV, Glatt SJ, Tsuang MT. Meta-analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders. *Am J Med Genet B Neuropsychiatr Genet* 2005 Feb 5;133B(1):110-5.
- (338) Neumeister A, Konstantinidis A, Stastny J, Schwarz MJ, Vitouch O, Willeit M, et al. Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. *Arch Gen Psychiatry* 2002 Jul;59(7):613-20.
- (339) Moreno FA, Rowe DC, Kaiser B, Chase D, Michaels T, Gelernter J, et al. Association between a serotonin transporter promoter region polymorphism and mood response during tryptophan depletion. *Mol Psychiatry* 2002;7(2):213-6.
- (340) Roiser JP, Blackwell AD, Cools R, Clark L, Rubinsztein DC, Robbins TW, et al. Serotonin transporter polymorphism mediates vulnerability to loss of incentive motivation following acute tryptophan depletion. *Neuropsychopharmacology* 2006 Oct;31(10):2264-72.
- (341) van der Lely AJ, de Herder WW. Carcinoid syndrome: diagnosis and medical management. *Arq Bras Endocrinol Metabol* 2005 Oct;49(5):850-60.
- (342) Sjoblom SM. Clinical presentation and prognosis of gastrointestinal carcinoid tumours.

References

- Scand J Gastroenterol 1988 Sep;23(7):779-87.
- (343) Arrindell WA, Barelds DP, Janssen IC, Buwalda FM, van der EJ. Invariance of SCL-90-R dimensions of symptom distress in patients with peri partum pelvic pain (PPPP) syndrome. *Br J Clin Psychol* 2006 Sep;45(Pt 3):377-91.
- (344) Oquendo MA, Hastings RS, Huang YY, Simpson N, Ogden RT, Hu XZ, et al. Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. *Arch Gen Psychiatry* 2007 Feb;64(2):201-8.
- (345) Uher R, McGuffin P. The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis. *Mol Psychiatry* 2008 Feb;13(2):131-46.
- (346) Wilhelm K, Mitchell PB, Niven H, Finch A, Wedgwood L, Scimone A, et al. Life events, first depression onset and the serotonin transporter gene. *Br J Psychiatry* 2006 Mar;188:210-5.
- (347) Kaufman J, Yang BZ, Douglas-Palumberi H, Houshyar S, Lipschitz D, Krystal JH, et al. Social supports and serotonin transporter gene moderate depression in maltreated children. *Proc Natl Acad Sci U S A* 2004 Dec 7;101(49):17316-21.
- (348) Deuschle M, Schweiger U, Gotthardt U, Weber B, Korner A, Schmider J, et al. The combined dexamethasone/corticotropin-releasing hormone stimulation test is more closely associated with features of diurnal activity of the hypothalamo-pituitary-adrenocortical system than the dexamethasone suppression test. *Biol Psychiatry* 1998 May 15;43(10):762-6.
- (349) Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. *J Psychiatr Res* 1994 Jul;28(4):341-56.
- (350) Nikisch G, Mathe AA, Czernik A, Thiele J, Böhner J, Eap CB, et al. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. *Psychopharmacology (Berl)* 2005 Oct;181(4):751-60.
- (351) Yuuki N, Ida I, Oshima A, Kumano H, Takahashi K, Fukuda M, et al. HPA axis normalization, estimated by DEX/CRH test, but less alteration on cerebral glucose metabolism in depressed patients receiving ECT after medication treatment failures. *Acta Psychiatr Scand* 2005 Oct;112(4):257-65.
- (352) Himmerich H, Zimmermann P, Ising M, Kloiber S, Lucae S, Kunzel HE, et al. Changes in the hypothalamic-pituitary-adrenal axis and leptin levels during antidepressant treatment. *Neuropsychobiology* 2007;55(1):28-35.
- (353) Aihara M, Ida I, Yuuki N, Oshima A, Kumano H, Takahashi K, et al. HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions. *Psychiatry Res* 2007 Aug 15;155(3):245-56.
- (354) Himmerich H, Binder EB, Kunzel HE, Schuld A, Lucae S, Uhr M, et al. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. *Biol Psychiatry* 2006 Oct 15;60(8):882-8.
- (355) Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. *Endocr Rev* 1996 Apr;17(2):187-205.

References

- (356) Ising M, Zimmermann US, Kunzel HE, Uhr M, Foster AC, Learned-Coughlin SM, et al. High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. *Neuropsychopharmacology* 2007 Sep;32(9):1941-9.
- (357) Calfa G, Kademian S, Ceschin D, Vega G, Rabinovich GA, Volosin M. Characterization and functional significance of glucocorticoid receptors in patients with major depression: modulation by antidepressant treatment. *Psychoneuroendocrinology* 2003 Jul;28(5):687-701.
- (358) Schleifer SJ, Keller SE, Meyerson AT, Raskin MJ, Davis KL, Stein M. Lymphocyte function in major depressive disorder. *Arch Gen Psychiatry* 1984 May;41(5):484-6.
- (359) Sauer J, Polack E, Wikinski S, Holsboer F, Stalla GK, Arzt E. The glucocorticoid sensitivity of lymphocytes changes according to the activity of the hypothalamic-pituitary-adrenocortical system. *Psychoneuroendocrinology* 1995;20(3):269-80.
- (360) Porstmann T, Ternynck T, Avrameas S. Quantitation of 5-bromo-2-deoxyuridine incorporation into DNA: an enzyme immunoassay for the assessment of the lymphoid cell proliferative response. *J Immunol Methods* 1985 Sep 3;82(1):169-79.
- (361) Kraan GP, Dullaart RP, Pratt JJ, Wolthers BG, de BR. Kinetics of intravenously dosed cortisol in four men. Consequences for calculation of the plasma cortisol production rate. *J Steroid Biochem Mol Biol* 1997 Sep;63(1-3):139-46.
- (362) Pratt JJ. Steroid immunoassay in clinical chemistry. *Clin Chem* 1978 Nov;24(11):1869-90.
- (363) Yagita Y, Kitagawa K, Sasaki T, Terasaki Y, Todo K, Omura-Matsuoka E, et al. Postischemic exercise decreases neurogenesis in the adult rat dentate gyrus. *Neurosci Lett* 2006 Nov 27;409(1):24-9.
- (364) Hammers HJ, Saballus M, Sheikzadeh S, Schlenke P. Introduction of a novel proliferation assay for pharmacological studies allowing the combination of BrdU detection and phenotyping. *J Immunol Methods* 2002 Jun 1;264(1-2):89-93.
- (365) Rupprecht R, Kornhuber J, Wodarz N, Lugauer J, Gobel C, Riederer P, et al. Lymphocyte glucocorticoid receptor binding during depression and after clinical recovery. *J Affect Disord* 1991 May;22(1-2):31-5.
- (366) Gratsias Y, Moutsatsou P, Chrysanthopoulou G, Tsagarakis S, Thalassinou N, Sekeris CE. Diurnal changes in glucocorticoid sensitivity in human peripheral blood samples. *Steroids* 2000 Dec;65(12):851-6.
- (367) Blom JM, Tascadda F, Carra S, Ferraguti C, Barden N, Brunello N. Altered regulation of CREB by chronic antidepressant administration in the brain of transgenic mice with impaired glucocorticoid receptor function. *Neuropsychopharmacology* 2002 May;26(5):605-14.
- (368) Barden N. Modulation of glucocorticoid receptor gene expression by antidepressant drugs. *Pharmacopsychiatry* 1996 Jan;29(1):12-22.
- (369) Pariante CM. Glucocorticoid receptor function in vitro in patients with major depression. *Stress* 2004 Dec;7(4):209-19.
- (370) Kaptein KI, De JP, Korf J, Spijker J, De GR, Van Der Werf SY. Random-mood interpretation of determinants for major depression. *Psychol Med* 2007 Sep;37(9):1261-71.
- (371) Van Der Werf SY, Kaptein KI, De JP, Spijker J, De GR, Korf J. Major depressive episodes

References

- and random mood. *Arch Gen Psychiatry* 2006 May;63(5):509-18.
- (372) Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. *JAMA* 1992 Mar 4;267(9):1244-52.
- (373) Checkley S. The neuroendocrinology of depression and chronic stress. *Br Med Bull* 1996 Jul;52(3):597-617.
- (374) Olivier B. Serotonin and aggression. *Ann N Y Acad Sci* 2004 Dec;1036:382-92.
- (375) Brocke B, Armbruster D, Muller J, Hensch T, Jacob CP, Lesch KP, et al. Serotonin transporter gene variation impacts innate fear processing: Acoustic startle response and emotional startle. *Mol Psychiatry* 2006 Dec;11(12):1106-12.
- (376) Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. *Nat Rev Neurosci* 2006 Feb;7(2):137-51.
- (377) Antonijevic IA. Depressive disorders -- is it time to endorse different pathophysiologies? *Psychoneuroendocrinology* 2006 Jan;31(1):1-15.
- (378) Hood SD, Bell CJ, Nutt DJ. Acute tryptophan depletion. Part I: rationale and methodology. *Aust N Z J Psychiatry* 2005 Jul;39(7):558-64.
- (379) Canli T, Lesch KP. Long story short: the serotonin transporter in emotion regulation and social cognition. *Nat Neurosci* 2007 Sep;10(9):1103-9.
- (380) Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. *Psychother Psychosom* 2003 Mar;72(2):71-9.
- (381) Healy D, Whitaker C. Antidepressants and suicide: risk-benefit conundrums. *J Psychiatry Neurosci* 2003 Sep;28(5):331-7.
- (382) Graham JE, Robles TF, Kiecolt-Glaser JK, Malarkey WB, Bissell MG, Glaser R. Hostility and pain are related to inflammation in older adults. *Brain Behav Immun* 2006 Jul;20(4):389-400.
- (383) Suarez EC, Krishnan KR. The relation of free plasma tryptophan to anger, hostility, and aggression in a nonpatient sample of adult men and women. *Ann Behav Med* 2006 Jun;31(3):254-60.